**Amanda Grant Smith, M.D.**

University of South Florida, Morsani College of Medicine, Tampa, Florida

**Address**

USF Health Byrd Alzheimer’s Institute

4001 E. Fletcher Ave, Tampa, FL 33613

Office: 813-974-4355

Email: asmith2@usf.edu

**Education**

Sidney Kimmel Medical College of Thomas Jefferson University: MD 9/1993-5/1997

(formerly Jefferson Medical College) Philadelphia, PA

Drexel University: no degree, completed one year of two year Master’s program 8/1992-8/1993

(formerly Hahnemann University) Philadelphia, PA

Emory University: BA Psychology & BA Biology 8/1988-5/1992

Atlanta, GA

**Postgraduate Training**

Fellowship in Geriatric Psychiatry, University of South Florida

Morsani College of Medicine, Tampa, FL 8/2001-9/2002

Residency in General Psychiatry, University of South Florida

Morsani College of Medicine, Tampa, FL 7/1997-8/2001

Diplomate of the American Board of Psychiatry and Neurology, Inc. 5/2003, 4/2013

Subspecialty Qualification in Geriatric Psychiatry 4/2004, 4/2013

Florida Medical License #ME 77616 Active through 1/31/2022

**Appointments**

Professor, Department of Psychiatry and Behavioral Neurosciences beginning 8/2020

University of South Florida Morsani College of Medicine, Tampa FL

Director of Clinical Research, USF Health Byrd Alzheimer’s Institute, Tampa, FL 3/2018-present

Associate Professor, Department of Psychiatry and Behavioral Neurosciences 8/2013-8/2020

University of South Florida Morsani College of Medicine, Tampa FL

Medical Director, USF Health Byrd Alzheimer’s Institute, Tampa, FL 7/2009-3/2018

Interim Director, Eric Pfeiffer Suncoast Alzheimer's Center, Tampa, FL 6/2008-7/2009

September 2008-July 2009

Assistant Director, USF Suncoast Gerontology Center, Tampa, FL 7/2004-5/2008

Assistant Professor, Department of Psychiatry and Behavioral Neurosciences 9/2003-8/2013

University of South Florida Morsani College of Medicine, Tampa, FL

Faculty Physician, USF Suncoast Gerontology Center, Tampa, FL 9/2002-7/2004

Visiting Instructor, Department of Psychiatry and Behavioral Neurosciences 9/2002-9/2003

University of South Florida Morsani College of Medicine, Tampa, FL

**Awards and Honors**

Best Doctors in America 2011- present

USF Health Leadership Institute Class of 2007

Joseph and Dora Camden Memorial Award for Suncoast Gerontology Center’s

Most Valuable Employee 2004, 2006

Director’s Award for Outstanding Service, Suncoast Gerontology Center's Development Board 2006

Edith P. Freedman Fellowship awarded to early career practitioner, Suncoast Gerontology Center 2002

John Adams Award, Florida Psychiatric Society 11/2001

Chairman’s Award for Scholarly and Creative Activity, Department of Psychiatry and Behavioral Neurosciences, USF Morsani College of Medicine, 6/2001

Ginsburg Fellow, Group for the Advancement of Psychiatry 1/1999-11/2000

**Teaching, Lecture**

“Diagnostic Advances and Treatment Strategies in Alzheimer’s Disease.” USF Neurology Resident lecture, 3/2018.

“AD and Dementia II” lecture for 2nd year medical students, Course 7, week 22. USF Health Morsani College of Medicine.

“Understanding the Institutional Review Board.” USF Geriatric Psychiatry Fellows lecture series. Annually, 5/2011- present.

“Clinical Trials.” USF Geriatric Psychiatry Fellows lecture series. Annually, 3/2011- present.

“The Diagnosis and Treatment of Alzheimer’s Disease.” USF Geriatric Psychiatry Fellows lecture series. Annually, 1/2011-present.

“Keeping your Brain Healthy.” Osher Lifelong Learning Institute of the University of South Florida. Annually, 2009-present.

“Dementia.” Medical Student Psychiatry Interest Coalition. USF College of Medicine. 12/5/ 2007. Tampa, FL.

Geriatric Case Discussion on Depression and Pseudodementia, 3rd year medical student psychiatry clerkship. Every other month, 6/2005-4/2007.

Geriatric psychiatry lectures on “Geriatric Depression” and “Management of Behavioral Symptoms in Dementia.” 3rd year medical student psychiatry clerkship. Every other month, 7/2003- 6/2005.

“Eating-Related Problems in Dementia Patients.” University Village nursing home staff.

11/192002. Tampa, FL.

**Teaching, Supervisory**

Advisor, Dr. Hanna Maeda, K01 Mentored Research Scientist Development Award 2020.

Outpatient clinical preceptor for USF Honors College student. Spring semester 2014.

Outpatient clinical preceptor for USF Nursing student. Fall semester 2013.

Outpatient clinical supervisor for 4 visiting neurologists from China. 2/2012-4/2012.

Doctoral Student Dissertation Committee for Elizabeth Hahn, USF School of Aging Studies. 2010-2012.

Outpatient clinical supervisor, 3rd year medical student. Primary Care- Special Populations (geriatrics). USF Morsani College of Medicine. Weekly, 2008-2011.

Geriatric Case Conference on Dementia, 3rd year medical student psychiatry clerkship. USF Morsani College of Medicine. Every other month, 6/2007-12/2007.

Outpatient clinical supervisor for ARNP Clinical Doctorate candidate. USF College of Nursing. 9/2006

Outpatient clinical supervisor for Geriatric Medicine fellow. USF Morsani Collge of Medicine. 9/2005

Thesis Director for undergraduate student, LaTangela Smith. USF Honors College. 2004-2005.

Enrichment supervisor to PGY-3 psychiatry residents. USF Morsani College of Medicine. Weekly, 2004-2009.

Outpatient clinical supervisor, 4th year medical student elective in geriatric psychiatry. USF Morsani Collge of Medicine. (Usually) weekly for 1-2 months/year. 2003-present. (MEL 8608)

Outpatient clinical supervisor, 3rd year medical student psychiatry clerkship. USF Morsani College of Medicine. Weekly 2003-2008.

Outpatient clinical supervisor to geriatric psychiatry fellow. USF Morsani College of Medicine. Weekly, 2002-present (when we have a fellow).

Examiner for Clinical Practice Exercise. Department of Psychiatry and Behavioral Neuroscience, USF Morsani College of Medicine. Annually, 2000-2016.

Led small group seminars for first year medical students as part of their Introduction to Behavioral Medicine course. USF Morsani College of Medicine. Annually, 2000-2006.

**Lectures by Invitation**

“Utilizing a Mobile Clinical Trials Unit: Lessons Learned from the First Three Years.” Alzheimer’s Association International Conference scheduled for July 2020.

“Alzheimer’s Disease Prevention and Risk Reduction.” 21st Annual University of South Florida Geriatric Institute: Excellence in Geriatric Health Care. 6/25/2019. Tampa, FL. CEU

“Toward an Earlier Diagnosis of Alzheimer’s Disease.” 20th Annual University of South Florida Geriatric Institute: Excellence in Geriatric Health Care. 6/13/2018. Tampa, FL. CEU

“Recognizing and Treating Alzheimer’s Disease: Moving Towards Early Diagnosis and Disease Management.” Detect: A 3-D Summit Meeting. 7/14/2016. Tampa, FL. CME.

“The Importance of Participation in Clinical Trials in Alzheimer’s Disease.” Annual Alzheimer’s Public Education Forum, 14th Annual Mild Cognitive Impairment Symposium. 1/16/2016, Miami Beach, FL.

“Alzheimer’s: A Woman’s Disease.” ALFA Senior Living Executive Conference. 5/5/2015. Tampa, FL. CEU

“Advances in the Diagnosis and Treatment of Alzheimer’s Disease.” Morton Plant Hospital Medical Surgical Lecture Series. 5/5/2015. Clearwater, FL. CME

“Advances in the Diagnosis and Treatment of Alzheimer’s Disease.” Bayfront Medical Center Grand Rounds. 2/5/2015. St. Petersburg, FL. CME

“Diagnostic Advancement & Treatment Strategies for Alzheimer’s Disease.” Morton Plant Hospital Medical Surgical Lecture Series. 10/29/2013. Clearwater, FL. CME

“Diagnostic Advances and Treatment Strategies for Alzheimer’s Disease.” Special lecture for the International Clinical Research Center. 9/24/2013. St. Ann’s University Hospital, Brno, Czech Republic.

"Alternative Treatments for Alzheimer's Disease." 14th Annual University of South Florida Geriatric Institute. Geriatrics: Critical Knowledge for Quality Care sponsored by USF Byrd Alzheimer’s Institute. 6/20/2012. Tampa, FL. CEU

“Prevent Alzheimer’s Now Before You Forget.” USF Health in the Villages Expert Lecture Series. 11/28/2011. The Villages, FL. (1,400 persons in attendance)

“The Rx for Preserving Drivers Who are Memory-Impaired.” 2011 Florida Conference on Aging: Aging: Through a New Lens. 8/23/2011. St. Petersburg Beach, FL. CME/CEU

“Toward an Earlier Diagnosis of Alzheimer’s Disease.” 13th Annual University of South Florida Geriatric Institute: The Challenges in Geriatric Health Care sponsored by USF Byrd Alzheimer’s Institute. 6/21/2011. Tampa, FL. CEU

“Advances in Alzheimer’s Disease Treatment and Research.” Florida Geriatric Society annual meeting: Advancing Clinical Care for Older Adults. 6/11/2011. Tampa, FL. CME

“Diagnosis and Management of Alzheimer’s Disease.” Morton Plant Hospital Medical Surgical Lecture Series. 5/3/2011. Clearwater, FL. CME

“Diagnosis and Management of Alzheimer’s Disease.” Morton Plant Hospital Medical Surgical Lecture Series. 10/12/2010. Clearwater, FL. CME

“Advances in the Diagnosis and Treatment of Alzheimer’s Disease.” 12th Annual University of South Florida Geriatric Institute: Excellence in Geriatric Care sponsored by USF Byrd Alzheimer’s Institute. 6/9/2010. Tampa, FL. CEU

“Other Types of Dementia that can Affect Capacity.” Hillsborough County Bar Association Educational Seminar. 12/16/2009. Tampa, FL. CLE

“Non-Alzheimer’s Dementia.” Training Event for Florida Association of Homes and Services for the Aging staff. 9/22/2009. Tampa, FL. CEU

“New Directions in Alzheimer’s Disease and Clinical Research.” 11th Annual University of South Florida Geriatric Institute sponsored by USF Suncoast Alzheimer’s & Gerontology Center. 6/24/2009. Tampa, FL. CEU

“Dementia.” James A. Haley VA Medical Center Geriatric Medicine Lecture series. 9/12/2008. Tampa, FL. CME

“New Directions in Alzheimer’s Treatment and Research.” 116th Annual Convention of the Florida Pharmacy Association. 7/12/2008. Orlando, FL. CEU

“New Directions in Alzheimer’s Clinical Research.” 10th Annual University of South Florida Geriatric Institute sponsored by USF Suncoast Alzheimer’s & Gerontology Center, USF Geriatric Education Center, USF School of Aging Studies, and USF College of Nursing. 6/13/2008. Tampa, FL. CEU

“Recognition and Management of Alzheimer’s Disease and Related Dementias in the Skilled Nursing Facility.” Florida chapter of the American Society of Consultant Pharmacists Annual Conference. 4/12/2008. Tampa, FL. CEU

“Optimizing Pharmacotherapeutic Benefit in Alzheimer’s Disease: Keys to Effective Disease Management.” Meeting of the Florida chapter of the American Society of Consultant Pharmacists. 1/29/2008. Ft. Lauderdale, FL. CEU

“Optimizing Pharmacotherapeutic Benefit in Alzheimer’s Disease: Keys to Effective Disease Management.” Meeting of the Florida chapter of the American Society of Consultant Pharmacists. 1/23/2008. Orlando, FL. CEU

“Optimizing Pharmacotherapeutic Benefit in Alzheimer’s Disease: Keys to Effective Disease Management.” Meeting of the Florida chapter of the American Society of Consultant Pharmacists.

1/22/2008. Tampa, FL. CEU

“Understanding Dementia.” James A. Haley VA Medical Center Geriatric Medicine Lecture series. 9/14/2007. Tampa, FL. CME

“Treatment of Dementia and Related Behavioral Problems.” Brandon Regional Hospital. 9/12/2007. Brandon, FL CME

“Understanding Dementia.” 44th Annual Conference of the Florida Association of Homes and Services for the Aging. 7/31/2007. Orlando, FL. CEU

“Lewy Body Dementia.” 9th Annual University of South Florida Geriatric Institute sponsored by USF Suncoast Alzheimer’s & Gerontology Center, USF Geriatric Education Center, USF School of Aging Studies, and USF College of Nursing. 6/13/2007. Tampa, FL. CEU

“Medications for Treating Alzheimer’s Disease and Behavior Management.” Brandon Regional Hospital Lecture Series. 2/21/2007. Brandon, FL. CME

“Advances in the Diagnosis and Treatment of Alzheimer’s Disease.” James A. Haley VA Medical Center Geriatric Medicine Lecture series. 10/6/2006. Tampa, FL. CME

“When the Dementia Diagnosis Isn’t Alzheimer’s.” Professional Guardian Association of Pinellas County Annual Conference. 9/26/2006. St. Petersburg, FL. CEU

“Lifestyle Changes that May Prevent Alzheimer’s Disease.” 8th Annual University of South Florida Geriatric Institute sponsored by USF Suncoast Gerontology Center, USF Geriatric Education Center, USF Department of Gerontology, and USF College of Nursing. 6/8/2006. Tampa, FL. CEU

“Pharmacologic Approaches to Behavior Management in Dementia.” 8th Annual University of South Florida Geriatric Institute sponsored by USF Suncoast Gerontology Center, USF Geriatric Education Center, USF Department of Gerontology, and USF College of Nursing. 6/8/2006. Tampa, FL. CEU

“Will a Healthy Lifestyle Prevent Alzheimer’s Disease?” University of South Florida Department of Psychiatry and Behavioral Medicine Geriatric Lecture series. 1/27/2006. Tampa, FL. CME

“Advances in the Diagnosis and Treatment of Alzheimer’s Disease.” University of South Florida Department of Psychiatry and Behavioral Medicine Grand Rounds. 12/9/2005. Tampa, FL. CME

“Advances in the Diagnosis and Treatment of Alzheimer’s Disease.” James A. Haley VA Medical Center Geriatric Medicine Lecture series. 11/18/2005. Tampa, FL. CME

“The Cutting Edge: Alzheimer’s Disease and Related Dementias.” Journey through Aging sponsored by USF Lakeland. 8/27/2005. Lakeland, FL. CEU

“The Diagnosis and Management of Dementia.” Neurology in the New Millennium sponsored by the USF Department of Neurology. 10/30/2004. Tampa, FL. CME

“When Memory Loss Is Not Alzheimer’s: Understanding Depression and the Other Dementias.” Alzheimer’s Disease: What Health Professionals Need to Know sponsored by USF Suncoast Gerontology Center and Lakeland Regional Medical Center. 12/2/2003. Lakeland, FL. CME/CEU

“Psychiatric Management of Dementia.” Strategies and Solutions in Geriatric Care. 5th Annual University of South Florida Geriatric Institute sponsored by USF Suncoast Gerontology Center, USF Geriatric Education Center, USF Department of Gerontology, and USF College of Nursing. 6/11/2003. Tampa, FL. CEU

“Topiramate Overdose: A Case Report and Literature Review.”

Fall meeting of the Florida Psychiatric Society. 11/3/2001. Miami, FL. CME

**Clinical Activities**

As medical director of the Byrd Institute, I oversaw and supported the Byrd Institute’s physicians, practitioners and staff, helping them to create comprehensive and effective care plans and to help patients, families, and caregivers. I maintain an active clinical practice focused on Alzheimer’s disease and other memory disorders. I have a strong focus on patient care, caregiver support, and community and health professional education. My work to date shows my commitment to brain health promotion and education, the provision of cognitive training, and enhancement of social and occupational function in the geriatric population. In addition, since 2016 I have served in my clinical capacity as an examiner for the National Football League’s 88 Plan due to my expertise in cognitive disorders.

**Innovations**

Development of nation’s first Mobile Clinical Trial unit for Alzheimer’s research. This mobile 400-square-foot research space is fully equipped to do most parts of a study visit, allowing us to bring trials to our subjects in their own communities rather than requiring them come to our clinic. Preliminary data suggests that we have been able to double enrollment in prevention trials and has garnered interest both nationally and internationally.

**Scholarly Activity**

Current Grants

Agency: NIH/NIA

ID:# 3U01AG062368-02S1

Title: Planning an Adaptive Clinical Trial of Cognitive Training to Improve Function and Delay Dementia: The Active Mind Trial

PI: Jerri Edwards PhD

Role on project: Sub-investigator

Percent effort: 2%

Total Award Amount: $314, 718

Project period: 9/1/2019-05/31/2020

Agency: NIH/NIA

ID:# R01AG056428-01A1

Title: Interventions to Attenuate Cognitive Decline: Keys to Staying Sharp

PI: Jerri Edwards PhD

Role on project: Sub-investigator

Percent effort: 2%

Total Award Amount: $719,902

Project period: 1/29/2018-1/8/2021

Past Grants

Agency: U.S. Department of Health and Human Services, Health Resources and Services Administration

ID:# U1QHP28739

Title: Geriatric Workforce Enhancement Program

PI: Rita D’Aoust, PhD; Kathryn Hyer, PhD

Role on project: Sub-investigator

Percent effort: 3%

Total Award Amount: $2,240,000

Project period: 1/1/2016-12/31/2018

Agency: The Leo and Anne Albert Charitable Trust.

ID# Pilot Project

Title: A Randomized, Double-Blind, Placebo-Controlled Six-month Crossover Study to Evaluate the Efficacy of Coconut Oil (Fuel for Thought™) Treatment for Subjects with Mild to Moderate Alzheimer’s Disease.

PI: Amanda G. Smith, MD

Total Award Amount: $166,850

Project Period: 04/22/2013-4/20/2016

Agency: USF Women’s Health Collaborative

ID# Faculty Seed Grant

Title A Pilot Study Investigating Biomarkers in Alzheimer’s Disease in Female Minorities.

PI Maj-Linda Selenica, PhD

Role on project: Co-investigator

Percent effort: 5%

Total award amount $9,627

Project period: 5/1/2013-4/30/2014

Agency: NIH/NIA

ID# P50-AG025711-04 Alzheimer's Disease Research Center (ADRC) grant

Title Florida ADRC Education Core

PI Huntington Potter, PhD

Role on Project: Sub-investigator

Percent effort: 10%

Total award amount $579,084

Project Period: 5/1/2005-3/31/2010

**Published Bibliography**

**Peer reviewed**

Sperling, RA, et al.\* Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurol. Published online April 6, 2020. \**as part of the A4 study team.*

Arendash G, Cao C, Abulaban H, Baranowski R, Wisniewski G, Becerra L, Andel R, Lin X, Zhang X, Wittwer D, Moulton J, Arrington J, Smith AG. A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer's Disease: Cognitive Enhancement and Associated Changes, CSF, Blood, and Brain Imaging. Journal of Alzheimer’s Disease, 2019 Sept 71(1) 57-82.

Kunkle BW, Grenier-Boley B, Sims R, Bis J, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, Sleegers K, Badarinarayan N, Jakobsdottir J, Hamilton-Nelson KL, Moreno-Grau S, Olaso R, Raybould R, Chen Y, Kuzma AB, Hiltunen M, Morgan T, Ahmad S, Vardarajan BN, Epelbaum J, Hoffmann P, Boada M, Beecham GW, Garnier JG, Harold D, Fitzpatrick AL, Valladares O, Moutet ML, Gerrish A, Smith AV, Qu L, Bacq D, Denning N, Jian X, Zhao Y, Del Zompo M, Fox NC, Choi SH, Mateo I, Hughes JT, Adams HH, Malamon J, Sanchez-Garcia F, Patel Y, Brody JA, Dombroski BA, Naranjo MCD, Daniilidou M, Eiriksdottir G, Mukherjee S, Wallon D, Uphill J, Aspelund T, Cantwell LB, Garzia F, Galimberti D, Hofer E, Butkiewicz M, Fin B, Scarpini E, Sarnowski C, Bush WS, Meslage S, Kornhuber J, White CC, Song Y, Barber RC, Engelborghs S, Sordon S, Voijnovic D, Adams PM, Vandenberghe R, Mayhaus M, Cupples LA, Albert MS, De Deyn PP, Gu W57, Himali JJ, Beekly D, Squassina A, Hartmann AM, Orellana A, Blacker D, Rodriguez-Rodriguez E, Lovestone S, Garcia ME, Doody RS, Munoz-Fernadez C, Sussams R, Lin H, Fairchild TJ, Benito YA, Holmes C, Karamujić-Čomić H, Frosch MP, Thonberg H, Maier W, Roschupkin G, Ghetti B, Giedraitis V, Kawalia A, Li S, Huebinger RM, Kilander L, Moebus S, Hernández I, Kamboh MI, Brundin R, Turton J, Yang Q, Katz MJ, Concari L, Lord J, Beiser AS, Keene CD, Helisalmi S, Kloszewska I, Kukull WA, Koivisto AM, Lynch A, Tarraga L, Larson EB, Haapasalo A, Lawlor B, Mosley TH, Lipton RB, Solfrizzi V, Gill M, Longstreth WT Jr, Montine TJ, Frisardi V, Diez-Fairen M, Rivadeneira F, Petersen RC, Deramecourt V, Alvarez , Salani F, Ciaramella A, Boerwinkle E, Reiman EM, Fievet N, Rotter JI, Reisch JS, Hanon O, Cupidi C, Andre Uitterlinden AG, Royall DR, Dufouil C, Maletta RG, de Rojas I, Sano M, Brice A, Cecchetti R, George-Hyslop PS, Ritchie K, Tsolaki M, Tsuang DW, Dubois B, Craig D, Wu CK, Soininen H, Avramidou D, Albin RL, Fratiglioni L, Germanou A, Apostolova LG, Keller L, Koutroumani M, Arnold SE, Panza F, Gkatzima O, Asthana S, Hannequin D, Whitehead P, Atwood CS, Caffarra P, Hampel H, Quintela I, Carracedo Á, Lannfelt L, Rubinsztein DC, Barnes LL, Pasquier F, Frölich L, Barral S, McGuinness B, Beach TG, Johnston JA, Becker JT, Passmore P, Bigio EH, Schott JM, Bird TD, Warren JD, Boeve BF, Lupton MK, Bowen JD, Proitsi P, Boxer A, Powell JF, Burke JR, Kauwe JSK, Burns JM, Mancuso M, Buxbaum JD, Bonuccelli U, Cairns NJ, McQuillin A, Cao C, Livingston G, Carlson CS, Bass NJ, Carlsson CM, Hardy J, Carney RM, Bras J, Carrasquillo MM, Guerreiro R, Allen M, Chui HC, Fisher E, Masullo C, Crocco EA, DeCarli C, Bisceglio G, Dick M, Ma L, Duara R, Graff-Radford NR, Evans DA, Hodges A, Faber KM, Scherer M, Fallon KB, Riemenschneider M, Fardo DW, Heun R, Farlow MR, Kölsch H, Ferris S, Leber M, Foroud TM, Heuser I, Galasko DR, Giegling I, Gearing M, Hüll M, Geschwind DH, Gilbert JR, Morris J, Green RC, Mayo K, Growdon JH, Feulner T, Hamilton RL, Harrell LE, Drichel D, Honig LS, Cushion TD, Huentelman MJ, Hollingworth P, Hulette CM, Hyman BT, Marshall R, Jarvik GP, Meggy A, Abner E, Menzies GE, Jin LW, Leonenko G, Real LM, Jun GR, Baldwin CT, Grozeva D, Karydas A, Russo G, Kaye JA, Kim R, Jessen F, Kowall NW, Vellas B, Kramer JH, Vardy E, LaFerla FM, Jöckel KH, Lah JJ, Dichgans M, Leverenz JB, Mann D, Levey AI, Pickering-Brown S, Lieberman AP, Klopp N, Lunetta KL, Wichmann HE, Lyketsos CG, Morgan K, Marson DC, Brown K, Martiniuk F, Medway C, Mash DC, Nöthen MM, Masliah E, Hooper NM, McCormick WC, Daniele A, McCurry SM, Bayer A, McDavid AN, Gallacher J, McKee AC, van den Bussche H, Mesulam M, Brayne C, Miller BL, Riedel-Heller S, Miller CA, Miller JW, Al-Chalabi A, Morris JC, Shaw CE, Myers AJ, Wiltfang J, O'Bryant S, Olichney JM, Alvarez V, Parisi JE, Singleton AB, Paulson HL, Collinge J, Perry WR, Mead S, Peskind E, Cribbs DH, Rossor M, Pierce A, Ryan NS, Poon WW, Nacmias B, Potter H, Sorbi S, Quinn JF, Sacchinelli E, Raj A, Spalletta G, Raskind M, Caltagirone C, Bossù P, Orfei MD, Reisberg B, Clarke R, Reitz C, Smith AD, Ringman JM, Warden D, Roberson ED, Wilcock G, Rogaeva E, Bruni AC, Rosen HJ, Gallo M, Rosenberg RN, Ben-Shlomo Y, Sager MA, Mecocci P, Saykin AJ, Pastor P, Cuccaro ML, Vance JM, Schneider JA, Schneider LS, Slifer S, Seeley WW, **Smith AG**, Sonnen JA, Spina S, Stern RA, Swerdlow RH, Tang M, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Wilhelmsen KC, Williamson J, Wingo TS, Woltjer RL, Wright CB, Yu CE, Yu L, Saba Y, Alzheimer Disease Genetics Consortium (ADGC), European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE),Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease Consortium (GERAD/PERADES), Pilotto A, Bullido MJ, Peters O, Crane PK, Bennett D, Bosco P, Coto E, Boccardi V, De Jager PL, Lleo A, Warner N, Lopez OL, Ingelsson M, Deloukas P, Cruchaga C, Graff C, Gwilliam R, Fornage M, Goate AM, Sanchez-Juan P, Kehoe PG, Amin N, Ertekin-Taner N, Berr C, Debette S, Love S, Launer LJ, Younkin SG, Dartigues JF, Corcoran C, Ikram MA, Dickson DW, Nicolas G, Campion D, Tschanz J, Schmidt H, Hakonarson H, Clarimon J, Munger R, Schmidt R, Farrer LA, Van Broeckhoven C, O'Donovan M, DeStefano AL, Jones L Haines JL, Deleuze JF, Owen MJ, Gudnason V, Mayeux R, Escott-Price V, Psaty BM, Ramirez A, Wang LS, Ruiz A, van Duijn CM, Holmans PA, Seshadri S, Williams J, Amouyel P, Schellenberg GD, Lambert JC, Pericak-Vance MA. Meta-analysis of genetic association with diagnosed Alzheimer's disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing. Nature Genetics, 2019 Mar; 51(3):414-430.

Chauhan G, et al\*. Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting. Neurology. January 29, 2019; 92 (5). \**as Alzheimer’s Disease Genetics Consortium author.*

Peloso, GM, et al\*. Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. Alzheimers Dement (Amst). 2018 Sep 22;10:595-598. \**As International Genomics of Alzheimer’s Project consortium author.*

Anttila V, Bulik-Sullivan, B, Finucane, HK, Walters, R, Bras. J, Duncan L, Escott-Price V, Falcone G, Gormley P, Malik PR, Patsopoulos N, Ripke S, Wei Z, Yu D, Lee PH, Turley P, Grenier-Boley B, Chouraki V, Kamatani Y, Berr C, Letenneur L, Hannequin D, Amouyel P, Boland A, Deleuze JF, Duron E, Vardarajan BN, Reitz C, Goate AM, Huentelman MJ, Kamboh MI, Larson EB, Rogaeva E, St George-Hyslop P, Hakonarson H, Kukull WA, Farrer LA, Barnes LL, Beach TG, Demirci FY, Head E, Hulette CM, Jicha GA, Kauwe JSK, Kaye JA, Leverenz JB, Levey AI, Lieberman AP, Pankratz VS, Poon WW, Quinn JF, Saykin AJ, Schneider LS, **Smith AG**, Sonnen JA, Stern RA, Van Deerlin VM, Van Eldik LJ, Harold D, Russo G, Rubinsztein DC, Bayer A, Tsolaki M, Proitsi P, Fox NC, Hampel H, Owen MJ, Mead S, Passmore P, Morgan K, Rossor M, Lupton M, Hoffmann P, Kornhuber J, Lawlor B, McQuillin A, Al-Chalabi A, Bis JC, Ruiz A, Boada M, Seshadri S, Beiser A, Rice K, van der Lee S, De Jager PL, Geschwind DH, Riemenschneider M, Riedel-Heller S, Rotter JI, Ransmayr G, Hyman BT, Cruchaga C, Alegret M, Winsvold B, Palta P, Farh KH, Cuenca-Leon E, Furlotte N, Kurth T, Ligthart L, Terwindt G, Freilinger T, Ran C, Gordon S, Borck G, Adams H, Lehtimäki T, Wedenoja J, Buring J, Schürks M, Hrafnsdottir M, Hottenga JJ, Penninx B, Artto V, Kaunisto M, Vepsäläinen S, Martin N, Montgomery G, Kurki M, Hämäläinen E, Huang H, Huang J, Sandor C, Webber C, Muller-Myhsok B, Schreiber S, Salomaa V, Loehrer E, Göbel H, Macaya A, Pozo-Rosich P, Hansen T, Werge T, Kaprio J, Metspalu A, Michel Ferrari M, Belin A, Maagdenberg A, Zwart JA, Dorret Boomsma D, Eriksson N, Olesen J, Chasman D, Nyholt D, Avbersek A, Baum L, Berkovic S, Bradfield J, Buono R, Catarino CB, Cossette P, Jonghe P, Depondt C, Dlugos D, Ferraro T, French J, Hjalgrim H, Jamnadas-Khota J, Kälviäinen R, Kunz W, Lerche H, Leu C, Lindhout D, Lo W, Lowenstein D, McCormack M, Møller R, Molloy A, Ng PW, Oliver K, Privitera M, Radtke R, Ruppert AK, Sander T, Schachter S, Schankin C, Scheffer I, Schoch S, Sisodiya S, Smith P, Sperling M, Striano P, Surges R, Thomas NG, Visscher F, Whelan CD, Zara F, Heinzen E, Marson A, Becker F, Stroink H, Zimprich F, Gasser T, Gibbs R, Heutink P, Martinez M, Morris H, Sharma M, Ryten M, Mok B, Pulit S, Bevan S, Holliday E, Attia J, Battey T, Boncoraglio G, Thijs V, Chen WM, Mitchell B, Rothwell P, Sharma P, Sudlow C, Vicente A, Markus H, Kourkoulis C, Pera J, Raffeld M, Silliman S, Perica VB,Thornton LM, Huckins LM, Rayner NW, Lewis CM, Gratacos M, Rybakowski F, Keski-Rahkonen A, Raevuori A, Hudson JI, Reichborn-Kjennerud T, Monteleone P, Karwautz A, Mannik K, Baker JH, O'Toole JK, Trace SE, Davis OSP, Helder S, Ehrlich S, Herpertz-Dahlmann B, Danner UN, van Elburg AA Clementi M, Forzan M, Docampo E, Lissowska J, Hauser J, Tortorella A, Gonidakis F, Tziouvas K, Papezova H, Yilmaz Z, Gudrun Wagner G, Cohen-Woods S, Herms S, Julia A, Rabionet R, Dick DM, Ripatti S, Andreasson OA, Espeseth T, Lundervold A, Steen VM, Pinto D, Scherer SW, Aschauer H, Schosser A, Lars Alfredsson L, Padyukov L, Halmi KA, Mitchell J, Strober M, Bergen AW, Kaye W, Szatkiewicz JP, Cormand B, Ramos-Quiroga JA, Sánchez-Mora C, Ribasés M, Casas M, Hervas A, Arranz MJ, Haavik J, Zayats T, Johansson S, Williams N, Dempfle A, Rothenberger A, Kuntsi J, Oades RD, Banaschewski T, Franke B, Buitelaar JK, Vasquez AA, Doyle AE, Reif A, Lesch KP, Freitag C, Rivero O, Palmason H, Romanos M, Langley K, Rietschel M, Witt SH, Dalsgaard S, Børglum A,Waldman I, Wilmot B, Molly N, Bau C, Crosbie J, Schachar R, Loo SK, McGough JJ, Grevet E, Medland SE, Robinson E, Weiss L, Bacchelli E, Bailey A, Bal V, Battaglia A, Betancur C, Bolton P, Cantor R, Celestino-Soper P, Dawson G, De Rubeis S, Duque F, Green A, Klauck SM, Leboyer M, Levitt P, Maestrini E, Mane S, Moreno-De-Luca D, Parr J, Regan R, Reichenberg A, Sandin S, Vorstman J, Wassink T,Wijsman E, Cook E, Santangelo S, Delorme R, Rogé B, Magalhaes T, Arking D, Schulze TG, Thompson RC, Strohmaier J, Matthews K, Melle I, Morris D, Blackwood D, McIntosh A, Bergen SE, Schalling M, Jamain S, Maaser A, Fischer SB, Reinbold CS, Fullerton JM, Guzman-Parra JG, Mayoral F, Schofield PR, Cichon S, Mühleisen TW, Degenhardt F, Schumacher J, Bauer M, Mitchell PB, Gershon ES, Rice J, Potash JB, Zandi PP, Craddock N, Ferrier IN, Alda M, Rouleau GA, Turecki G, Ophoff R, Pato C, Anjorin A, Stahl E, Markus Leber M, Czerski PM, Cruceanu C, Jones RI, Posthuma D, Andlauer T, Forstner AJ, Streit F, Baune BT, Air T, Sinnamon G, Wray N, MacIntyre D, Porteous D, Homuth G, Rivera M, Grove J, Middeldorp C, Hickie I, Pergadia M, Mehta D, Smit JH, Jansen R, de Geus E, Dunn E, Li Q, Nauck M, Schoevers RA, Beekman ATF, Knowles JA, Viktorin A, Arnold P, Barr C, Bedoya-Berrio G, Bienvenu O, Brentani H, Burton C, Camarena B, Cappi C, Cath D, Cavallini M, Cusi D, Darrow S, Denys D, Derks E, Dietrich A, Fernandez T, Figee M, Freimer N, Gerber G, Grados M, Greenberg E, Hartmann A, Hirschtritt M, Hoekstra P, Huang A, Huyser C, Illmann C, Jenike M, Kuperman S, Leventhal B, Lochner C, Lyon G, Macciardi F, Madruga-Garrido M, Malaty IA, Maras A, McGrath L, Miguel E, Mir P, Nicolini H, Okun MS, Pakstis A, Piacentini J, Pittenger C, Plessen K, Ramensky V, Ramos EM, Reus V, Richter M, Riddle M, Robertson M, Roessner V, Rosário M, Sandor P, Stein D,Tsetsos F, Van Nieuwerburgh F, Weatherall S, Wendland J, Wolanczyk T, Worbe Y, Goes F, McLaughlin N, Nestadt PS, Grabe HJ, Depienne C, Konkashbaev A, Lanzagorta N, Valencia-Duarte A, Bramon E, Buccola N, Cahn W, Cairns M, Chong S, Cohen D, Crespo-Facorro B, Crowley J, Davidson M, DeLisi L, Dinan T, Donohue G, Drapeau E, Duan J, Haan L, David Hougaard D, Karachanak-Yankova S, Khrunin A, Klovins J, Kucinskas V, Keong JLC, Limborska S, Loughland C, Lönnqvist J, Maher B, Mattheisen M, McDonald C, Murphy K, Nenadic I, Jim Os J, Pantelis C, Pato M, Petryshen T, Quested D, Roussos P, Sanders A, Schall U, Schwab S, Sim K, So HC, Stögmann E, Subramaniam M, Toncheva D, Waddington J, Walters J, Cheng W, Cloninger R, Curtis D, Henskens F, Mattingsdal M, Oh SY, Scott R, Webb B, Churchhouse C, Breen G, Bulik C, Daly M, Dichgans M ,Faraone SV, Guerreiro R, Holmans P, Kendler K, Koeleman B, Mathews CA, Price A, Scharf J, Sklar, P Williams J, Wood N, Cotsapas C, Palotie A, Smoller J, Sullivan P, Rosand J, Corvin A, Neale BM, on behalf of the Brainstorm consortium. Analysis of Shared Heritability in Common Disorders of the Brain. Science. 2018 Jun 22;360(6395).

Sims, R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, Martin ER, Grenier-Boley B, Heilmann-Heimbach S, Chouraki V, Kuzma AB, Sleegers K, Vronskaya M, Ruiz A, Graham RR, Olaso R, Hoffmann P, Grove ML, Vardarajan BN, Hiltunen M, Nöthen MM, White CC, Hamilton-Nelson KL, Epelbaum J, Maier W, Choi SH, Beecham GW, Dulary C, Herms S, Smith AV, Funk CC, Derbois C, Forstner AJ, Ahmad S, Li H, Bacq D, Harold D, Satizabal CL, Valladares O, Squassina A, Thomas R, Brody JA, Qu L, Sánchez-Juan P, Morgan T, Wolters FJ, Zhao Y, Garcia FS, Denning N, Fornage M, Malamon J, Naranjo MCD, Majounie E, Mosley TH, Dombroski B, Wallon D, Lupton MK, Dupuis J, Whitehead P, Fratiglioni L, Medway C, Jian X, Mukherjee S, Keller L, Brown K, Lin H, Cantwell LB, Panza F, McGuinness B, Moreno-Grau S, Burgess JD, Solfrizzi V, Proitsi P, Adams HH, Allen M, Seripa D, Pastor P, Cupples LA, Price ND, Hannequin D, Frank-García A, Levy D, Chakrabarty P, Caffarra P, Giegling I, Beiser AS, Giedraitis V, Hampel H, Garcia ME, Wang X, Lannfelt L, Mecocci P, Eiriksdottir G, Crane PK, Pasquier F, Boccardi V, Henández I, Barber RC, Scherer M, Tarraga L, Adams PM, Leber M, Chen Y, Albert MS, Riedel-Heller S, Emilsson V, Beekly D, Braae A, Schmidt R, Blacker D, Masullo C, Schmidt H, Doody RS, Spalletta G, Longstreth WT Jr, Fairchild TJ, Bossù P, Lopez OL, Frosch MP, Sacchinelli E, Ghetti B, Yang Q, Huebinger RM, Jessen F, Li S, Kamboh MI, Morris J, Sotolongo-Grau O, Katz MJ, Corcoran C, Dunstan M, Braddel A, Thomas C, Meggy A, Marshall R, Gerrish A, Chapman J, Aguilar M, Taylor S, Hill M, Fairén MD, Hodges A, Vellas B, Soininen H, Kloszewska I, Daniilidou M, Uphill J, Patel Y, Hughes JT, Lord J, Turton J, Hartmann AM, Cecchetti R, Fenoglio C, Serpente M, Arcaro M, Caltagirone C, Orfei MD, Ciaramella A, Pichler S, Mayhaus M, Gu W, Lleó A, Fortea J, Blesa R, Barber IS, Brookes K, Cupidi C, Maletta RG, Carrell D, Sorbi S, Moebus S, Urbano M, Pilotto A, Kornhuber J, Bosco P, Todd S, Craig D, Johnston J, Gill M, Lawlor B, Lynch A, Fox NC, Hardy J; ARUK Consortium, Albin RL, Apostolova LG, Arnold SE, Asthana S, Atwood CS, Baldwin CT, Barnes LL, Barral S, Beach TG, Becker JT, Bigio EH, Bird TD, Boeve BF, Bowen JD, Boxer A, Burke JR, Burns JM, Buxbaum JD, Cairns NJ, Cao C, Carlson CS, Carlsson CM, Carney RM, Carrasquillo MM, Carroll SL, Diaz CC, Chui HC, Clark DG, Cribbs DH, Crocco EA, DeCarli C, Dick M, Duara R, Evans DA, Faber KM, Fallon KB, Fardo DW, Farlow MR, Ferris S, Foroud TM, Galasko DR, Gearing M, Geschwind DH, Gilbert JR, Graff-Radford NR, Green RC, Growdon JH, Hamilton RL, Harrell LE, Honig LS, Huentelman MJ, Hulette CM, Hyman BT, Jarvik GP, Abner E, Jin LW, Jun G, Karydas A, Kaye JA, Kim R, Kowall NW, Kramer JH, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lunetta KL, Lyketsos CG, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Morris JC, Murrell JR, Myers AJ, O'Bryant S, Olichney JM, Pankratz VS, Parisi JE, Paulson HL, Perry W, Peskind E, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rogaeva E, Rosen HJ, Rosenberg RN, Sager MA, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, **Smith AG**, Sonnen JA, Spina S, Stern RA, Swerdlow RH, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Wilhelmsen KC, Williamson J, Wingo TS, Woltjer RL, Wright CB, Yu CE, Yu L, Garzia F, Golamaully F, Septier G, Engelborghs S, Vandenberghe R, De Deyn PP, Fernadez CM, Benito YA, Thonberg H, Forsell C, Lilius L, Kinhult-Stählbom A, Kilander L, Brundin R, Concari L, Helisalmi S, Koivisto AM, Haapasalo A, Dermecourt V, Fievet N, Hanon O, Dufouil C, Brice A, Ritchie K, Dubois B , Himali JJ, Keene CD, Tschanz J, Fitzpatrick AL, Kukull WA, Norton M, Aspelund T, Larson EB, Munger R, Rotter JI, Lipton RB, Bullido MJ, Hofman A, Montine TJ, Coto E, Boerwinkle E, Petersen RC, Alvarez V, Rivadeneira F, Reiman EM, Gallo M, O'Donnell CJ, Reisch JS, Bruni AC, Royall DR, Dichgans M, Sano M, Galimberti D, St George-Hyslop P, Scarpini E, Tsuang DW, Mancuso M, Bonuccelli U, Winslow AR, Daniele A, Wu CK; GERAD/PERADES, CHARGE, ADGC, EADI, Peters O, Nacmias B, Riemenschneider M, Heun R, Brayne C, Rubinsztein DC, Bras J, Guerreiro R, Al-Chalabi A, Shaw CE, Collinge J, Mann D, Tsolaki M, Clarimón J, Sussams R, Lovestone S, O'Donovan MC, Owen MJ, Behrens TW, Mead S, Goate AM, Uitterlinden AG, Holmes C, Cruchaga C, Ingelsson M, Bennett DA, Powell J, Golde TE, Graff C, De Jager PL, Morgan K, Ertekin-Taner N, Combarros O, Psaty BM, Passmore P, Younkin SG, Berr C, Gudnason V, Rujescu D, Dickson DW, Dartigues JF, DeStefano AL, Ortega-Cubero S, Hakonarson H, Campion D, Boada M, Kauwe JK, Farrer LA, Van Broeckhoven C, Ikram MA, Jones L, Haines JL, Tzourio C, Launer LJ, Escott-Price V, Mayeux R, Deleuze JF, Amin N, Holmans PA, Pericak-Vance MA, Amouyel P, van Duijn CM, Ramirez A, Wang LS, Lambert JC, Seshadri S, Williams J, Schellenberg GD. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet. 2017 Sep; 49(9):1373-1384.

Relkin, NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano , Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017 May 2;88(18):1768-1775. *\*As Alzheimer’s Disease Cooperative Study author.*

Grewal R, Haghighi, Huang S, Smith AG, Cao C, Lin X, Lee DC, Teten N, Hill AM, Selenica MB. Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients. Alzheimer’s Res Ther. 2016 Oct 18;8(1):43.

Jun GR, et al.\*A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry (2016) 21, 108–117 \**as International Genomics of Alzheimer’s Project Consortium author.*

Haghighi M, Smith AG, Morgan D, Small B, Huang S. Identifying Cost-Effective Predictive Rules of Amyloid-β Level by Integrating Neuropsychological Tests and Plasma-Based Markers. J Alzheimer’s Dis. 2015: 43:1261-7

Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS; Alzheimer's Disease Cooperative Study. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20;85(16):1383-91 *\*as Alzheimer’s Disease Cooperative Study author.*

Grieco JC, Ciarlone SL, Gieron-Korthals M, Schoenberg MR, Smith AG, Philpot RM, Heussler HS, Banko JL, Weeber, EJ .An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome. BMC Neurology 2014: 14:232

Benbadis S, Sanchez-Ramos J, Bozorg A, Giarratano M, Kalidas K, Katzin L, Robertson R, Smith AG, Vu T, Zesiewicz T. Medical Marijuana in Neurology. Expert Review of Neurotherapeutics 2014: 14:1453-65

Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease.

Neurology. 2014 Apr 29;82(17):1536-42 *\*as Alzheimer’s Disease Cooperative Study author.*

Naj AC, et al\*. Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease: A Genome-Wide Association Study. JAMA Neurology 2014: 71(11):1394-404 \**as Alzheimer’s Disease Genetics Consortium author.*

Lambert, JC, et al\*. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics 2013: 45(12):1452-8 *\*as Alzheimer’s Disease Genetics Consortium author.*

Miyashita, A, et al\*. SORL1 is Genetically Associated with Late Onset Alzheimer’s Disease in Japanese, Koreans, and Caucasians. PLoS One. 2013; 8(4):e58618 *\*as Alzheimer’s Disease Genetics Consortium author.*

Daily, J; Smith, AG; Weeber, EJ. Spatial and Temporal Silencing of the Human Maternal UBE3A gene. European Journal of Paediatric Neurology 2012: 16(6):587-91.

Morgan, D and Smith, AG. Why Age (and Timing) Really Matters in Developing Drugs for Neurodegenerative Disease. Therapy 2011; 8(5): 459-461.

Quinn, JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS. Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer’s Disease: A Randomized Trial. JAMA 2010; 304 (17): 1903-1911 *\*as participating investigator.*

**Case reports**

Smith, AG; Montealegre-Orjuela M; Douglas JE; Jenkins EA. Venlafaxine for Pathological Crying After Stroke. Journal of Clinical Psychiatry 2003; 64(6): 731-732.

Smith, AG; Brauer, HR; Catalano, G; Catalano, MC. Topiramate Overdose: A Case Report and Literature Review. Epilepsy and Behavior 2001; 2(6): 603-607.

**Books, textbooks, chapters**

Smith, AG: Coping with the Changes in Medicine that Affect Residency Training, in Foreman, T, Dickstein, LJ, Garakani, A (eds): A Resident’s Guide to Surviving Psychiatric Training, 2nd Edition. American Psychiatric Association, Arlington, VA, 2007. pp138-139.

Smith, AG: Dealing with Managed Care in the Outpatient Setting, in Foreman, T, Dickstein, LJ, Garakni, A (eds): A Resident’s Guide to Surviving Psychiatric Training, 2nd Edition. American Psychiatric Association, Arlington, VA, 2007. pp140-142.

**Other**

Regular guest health columnist for The Tampa Tribune (4 You) 2006-2012.

**Other Research and Creative Achievements**

**Poster Presentations**

Raman R, Smith AG, Jimenez-Maggiora G, Ernstrom K, So JS, Wong M, Aisen PS, Sperling RA, Aggarwal NT. Diversity & Inclusion in Alzheimer’s Disease Clinical Trials Workforce: A Survey to Assess Baseline Membership and Climate in the Alzheimer’s Clinical Trials Consortium (ACTC). Clinical Trials on Alzhemer’s Disease. December 5, 2019, San Diego, California.

Qureshi IA, Messer K, Erickson K, Berman RM, Revta C, Oltersdorf T, Huisa B, Jacobs D, Salmon D, Galasko D, Obisesan TO, Aggarwal NT, Mintzer J, Heidebrink J, Smith AG, Reed MN, Hunsberger HC, Donahue L, Gentile K , Stock DA, Coric V, Feldman H. Efficacy and Safety of Trigriluzole (BHV-4157) in Patients with Mild to Moderate Alzheimer’s Dementia: T2 PROTECT AD Phase 2 Study Design. Clinical Trials on Alzheimer’s Disease. October 25, 2018, Barcelona, Spain.

Smith, AG, Smith, J, Morgan D. Utilizing a Mobile Clinical Trial Unit to Enhance Recruitment in Prevention Trials for Alzheimer’s Disease. Alzheimer’s Association International Conference. July 24, 2018. Chicago, IL.

Smith, J, Smith AG, Morgan D. Enhancing Florida Clinical Trial Recruitment and Executing Research in Alzheimer’s Disease through Mobile Clinical Trial Unit. Alzheimer’s Association International Conference. July 25, 2016. Toronto, Canada.

Smith, J, Smith, AG, Morgan, D. Enhancing Clinical Trial Recruitment in Alzheimer’s Disease Research through Community Based Mobile Clinical Trial Unit. Clinical Trials on Alzheimer’s Disease. November 5, 2015. Barcelona, Spain.

Hill, AM, Grewal R, Smith AG, Teten N, Casey S, Onydimma Smith J, Rodrigo K, Selenica MB. A Pilot Study Investigating Biomarkers in Alzheimer’s Disease, Focusing on Female Minority Patients. USF Health Women’s Health Collaborative. May 14, 2014. Tampa, FL.

Haghighi M, Smith AG, Morgan D, Small B, Huang S. Identifying Cost-Effective Predictive Rules of Amyloid-β Level by Integrating Neuropsychological Tests and Plasma-Based Markers. Human Amyloid Imaging. January 17, 2014. Miami Beach, FL.

Smith, AG. Grief and Its Effect on the Decision to Place a Demented Loved One in Long-Term Care. Future Leaders in Psychiatry sponsored by Emory University School of Medicine. April 16, 2005. Palm Beach, FL.

**Clinical Trial Activity- ongoing**

Site Principal Investigator: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease, Phase II. I5T-MC-AACI (TRAILBLAZER-ALZ2). Eli Lilly.

Site Principal Investigator: Phase 3b open-label, multicenter, safety study of BIIB037 (Aducanumab) in subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205Study. 221AD304 (EMBARK) Biogen MA Inc./Biogen Idec Research Limited.

Site Principal Investigator: Mobile Assessment of Neurocognitive and Psychological Function: A Case-Controlled, Prospective Observational Non-inferiority Study in Age-matched Cohorts of Healthy Adults and Adults with Mild Cognitive Impairment. MIRO\_002\_2018. Miro Health 2019. Contracted amount pending.

Site Principal Investigator: Mobile Assessment of Neurocognitive and Psychological Function: A Study of Test/re-test Reliability in Cohorts of Younger and Older Adult Healthy Volunteers. MIRO\_003\_2018. Miro Health 2019. Contracted amount pending.

Site Principal Investigator: A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease (Clarity AD). Eisai 2019. Contracted amount pending.

Site Principal Investigator: A Phase 2 Randomized Double‐Blind Placebo‐Controlled Trial to Evaluate the Efficacy and Safety of BHV‐4157 in Patients with Mild to Moderate Alzheimer’s Disease: (T2 PROTECT). Biohaven 2019. Contracted amount $283,850.

Site Principal Investigator: An Extension Study of ABBV-8E12 in Early Alzheimer's Disease. M15-570. AbbVie. Contracted amount $1,079,551.

Site Principal Investigator: Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) Protocol. Alzheimer’s Therapeutic Research Institute. ATRI-001. 2017. Contracted amount $324,314.

Site Principal Investigator: A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects

with Early Alzheimer's Disease. M15-566. AbbVie 2016. Contract amount $417, 440.

Site Principal Investigator: Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease - Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the A4 LEARN Study. Alzheimer’s Therapeutic Research Institute 2015. Contracted amount $414,700.

Site Principal Investigator: Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study.) Eli Lilly & Co./Alzheimer’s Therapeutic Research Institute. H8A-MC-LZAZ(a)/ADC-040-A4. 2013. Contracted amount $1,198,855.

**Clinical Trial Activity- completed**

Principal Investigator: A Phase 1 Study to Evaluate the Safety and Efficacy of Transcranial Electromagnetic Treatment (TEMT) for the Treatment of Alzheimer’s Disease. EM-1000-1. NeuroEM Therapeutics 2017.

Contracted amount $222,000.

Site Principal Investigator: A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GENERATION 2). CCNP520A2202J. Novartis 2018. Contracted amount $1,100,000.

Site Principal Investigator: A Randomized, Double-blind, Placebo-controlled, Two Cohort

Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (GENERATION 1). CAPI015A2201J. Novartis 2018. Contracted amount $572,500.

Site Principal Investigator: Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) (GRADUATE2). WN39658. Hoffman LaRoche 2018. Contracted amount $135,000.

Site Principal Investigator: A Phase 3, Multi-Center, Randomized, Double-blind, placebo-controlled, parallel-group efficacy and safety study of Crenezumab in Patients with Prodromal to Mild Alzheimer’s Disease. (CREAD study.) BN29552. Roche 2016. Contract amount $609,500.

Site Principal Investigator (2016), Study Physician: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease. 221AD301. Biogen MA, Inc. (initial site PI: B. Ashok Raj.) 2015. Contract amount $443,885.

Site Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Disease Dementia (DAYBREAK Study). I8D-MC-AZET

Eli Lilly and Company 2016. Contract amount $595,000.

Site Principal Investigator: A Phase 2A Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of 50 mg and 100 mg of SUVN-502 in Subjects with Moderate Alzheimer’s Disease Currently Treated with Donepezil Hydrochloride and Memantine Hydrochloride. CTP2S1502HT6. Suven Life Sciences Ltd. 2016. Contract amount $63,245.

Site Principal Investigator: A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects who are Asymptomatic At Risk for Developing Alzheimer’s Dementia (EARLY). 54861911ALZ2003. Janssen Research & Development 2016. Contract amount $713,364.

Site Principal Investigator: Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage with Evidence Development Longitudinal Cohort Study. American College of Radiology Imaging Network. 2016.

Site Principal Investigator: A Phase 2a Multi-Center Study of 18FDG-PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease. (FYN study.) Alzheimer’s Therapeutic Research Institute 2015.

Site Principal Investigator: An open label, multicenter study, evaluating the safety and imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheimer’s disease. Avid Radiopharmaceuticals 2014.

Site Principal Investigator (2016): Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) Versus Placebo. H8A-MC-LZAX. Eli Lilly & Co. (initial site PI: B. Ashok Raj.) 2013.

Site Principal Investigator: A Randomized, Placebo-Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild Cognitive Impairment. MK 8931-019-P07738. Merck Sharp & Dohme Corp. 2013. Contract amount $639,606.

Site Principal Investigator: A Randomized, Placebo-Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer’s Disease. MK 8931-017-P07738. Merck Sharp & Dohme Corp. 2013

Site Principal Investigator (2016): Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid ß Antibody in Patients with Alzheimer’s Disease. (EXPEDITION 3) H8A-MC-LZAO(c). Eli Lilly and Co. (initial site PI: B. Ashok Raj.)2013.

Site Principal Investigator (2016): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer’s Disease. TR-237-005. TauRX. (initial PI: B. Ashok Raj.) 2013.

Site Principal Investigator: A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomized Design and Dose Regimen-Finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 In Subjects with Early Alzheimer’s Disease. BAN2401-G000-20.Eisai, Inc. 2013

Site Principal Investigator: A Multi-Center, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients with Mild to Moderate Alzheimer’s Disease. ADC-037-RES. Alzheimer’s Disease Cooperative Study. 2012

Site Principal Investigator, Study physician: A Multi-Center, Randomized, Double Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic effects of BMS-708163 in the Treatment of Patients with Prodromal Alzheimer’s Disease. CN156018. Bristol-Myers Squibb. 2009.

Site Principal Investigator: A Multi-Center, Randomized, Double Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic effects of BMS-708163 in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease. CN156013. Bristol-Myers Squibb. 2009.

Site Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer’s Disease. ELND005-AD201. Élan Pharmaceuticals, Inc. 2008.

Site Principal Investigator: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Efficacy and Safety of Eighteen Months of Treatment with PF-04494700 (TTP488) in Participants with Mild to Moderate Alzheimer’s Disease. ADCS-RAGE; Pfizer B0341002. Alzheimer’s Disease Cooperative Study and Pfizer. 2008.

Site Principal Investigator (2008): A Randomized, Double-blind, Placebo-controlled, Add-on Three-arm Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IVIG, 10%) for the Treatment of Mild to Moderate Alzheimer’s Disease. ADCS-GLAD; Baxter 160701. Alzheimer’s Disease Cooperative Study and Baxter Healthcare Corporation. (initial PI: Eric Pfeiffer.) 2007.

Site Principal Investigator (2008): A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E4 Non-carriers. ELN115727-301. Élan Pharmaceuticals, Inc., & Wyeth. (initial PI: Eric Pfeiffer.) 2007.

Site Principal Investigator (2008): A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) In Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E4 Carriers. ELN115727-302. Élan Pharmaceuticals, Inc., & Wyeth. (initial PI: Eric Pfeiffer.) 2007.

Site Principal Investigator (2008): Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Mild Dementia of the Alzheimer’s Type. MPC-7869-05-009. Myriad Pharmaceuticals, Inc. (initial PI: Eric Pfeiffer.) 2007.

Site Principal Investigator (2008): Multi-Center Trial to Evaluate Home-Based Assessment Methods for Alzheimer Disease Prevention Research in People Over 75 Years Old. ADC-030-HBA. Alzheimer’s Disease Cooperative Study. (initial PI: Eric Pfeiffer.) 2007.

Site Principal Investigator (2008): A Randomized Double-Blind Placebo-Controlled Trial of the Effects of Docosahexaenoic Acid (DHA) in Slowing the Progression of Alzheimer’s Disease. ADC-027-DHA. Alzheimer’s Disease Cooperative Study. (initial PI: Eric Pfeiffer.) 2006.

Site Principal Investigator (2008): A Phase 3 Multinational, Randomized, Double-blind, Placebo-controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living, and Global Function in Subjects with Mild Dementia of the Alzheimer’s Type. MPC-7869-05-010. Myriad Pharmaceuticals, Inc. (initial PI: Eric Pfeiffer.) 2006.

Site Principal Investigator (2008): A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild Dementia of the Alzheimer’s Type. MPC-7869-04-005. Myriad Pharmaceuticals, Inc. (initial PI: Eric Pfeiffer.) 2005.

Site Principal Investigator (2008): A Multi-center, Double-blind, Placebo-controlled Therapeutic Trial to Determine Whether Natural Huperzine A Improves Cognitive Function. ADC-023-HU. Alzheimer’s Disease Cooperative Study. (initial PI: Eric Pfeiffer.) 2004.

**Service**

**National**

Member, Science Advisory Board, Hilarity for Charity November 2019-present.

Application Review Committees, Fellowship and Certificate tracks, Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (NIA/AA IMPACT-AD Course) scheduled for Sept 2020, San Diego, California. November 2019-present.

Co-chair, Outreach and Policy subcommittee, ACTC Inclusion, Diversity, and Education in Alzheimer’s disease Clinical Trials (IDEA-CT) Committee, 2018-present.

Member, ACTC Inclusion, Diversity, and Education in Alzheimer’s disease Clinical Trials (IDEA-CT) Committee 2018-present.

Voting Member, Steering Committee, Alzheimer’s Clinical Trial Consortium (ACTC), 2018-present.

Scientific Review Panel for Research Centers of Excellence program, Lewy Body Dementia Association, 2017- present.

Member, Global Alzheimer’s Platform (GAP) network 2017-present.

Voting Member, Alzheimer’s Therapeutic Research Institute (ATRI) partnership associated with the University of Southern California Keck School of Medicine,2015-present.

Voting Member, Steering Committee, Alzheimer’s Disease Neuroimaging Initiative (ADNI). 2011-present.

Reviewer, Alzheimer’s & Dementia 2010 to present.

Examiner, American Board of Psychiatry and Neurology Psychiatry (ABPN) Psychiatry Part II Oral Exams, Boston, MA. 4/2009.

Voting Member, Steering Committee, Alzheimer’s Disease Cooperative Study (ADCS), based out of the University of California, San Diego. 2008-present.

Editorial Board Consultant, American Journal of Geriatric Pharmacotherapy 2007.

Reviewer for Evashwick, C: The Continuum of Long-Term Care, 3rd Ed. Thomson Delmar Learning, Clifton Park, NY, 2004.

Reviewer, Journal of Mental Health and Aging 2003.

Committee on Aging, Group for the Advancement of Psychiatry. 1999-2000.

**State & Local**

Member, subcommittee 1.1 on Alzheimer's Disease and Related Dementias (ADRD) - in the State of Florida State Health Improvement Plan (SHIP) 8/2019-present.

Faculty Representative, USF Athletics Council 1/2019 to present.

Member, State of Florida Ed and Ethel Moore Alzheimer’s Disease Research Grant Advisory Board. 10/2014-10/2016, appointed by state Surgeon General.

Recording Secretary, Board of Directors, Tampa Jewish Family Services. 6/2012-6/2014.

Board of Directors, Tampa Jewish Family Services. 6/2011-6/2014.

Event planning committee. CURE-RUN benefiting USF Health Byrd Alzheimer’s Institute. 2011-2013.

USF Health Byrd Alzheimer’s Institute Scientific Advisory Board. 2009-present.

USF Health Byrd Alzheimer’s Institute Management Committee 2009-present.

USF Institutional Review Board subcommittee on consent of cognitively impaired subjects. 2/2009-9/2014.

Volunteer, Alzheimer's Association Walk to End Alzheimer's. Annually, 2008-present.

USF Clinical and Translational Scientific Institute & Neuroscience Signature Program Protocol Review Committee. 2008-2011.

Volunteer, National Memory Screening Day. Annually, 2007-present.

USF Institutional Review Board Medical Board IRB-01A. 7/2006- 9/2014.

Executive Committee of the Development Board, USF Suncoast Alzheimer’s and Gerontology Center. 2005-2009.

Auction Chair, USF Suncoast Alzheimer’s and Gerontology Center's Victory Ball, 2005-2008.

Recruitment Committee, Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine. 2004-2008.

Research Committee, Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine. 2003-2008.

Psychiatry Representative, Continuing Professional Education Advisory Committee, University of South Florida Morsani College of Medicine. 2003-2006.

Geriatric Fellowship Committee, Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine 2002-present.

Executive Committee, USF Suncoast Alzheimer’s and Gerontology Center. 2002-2008.

Psychiatry Representative, Utilization Review Committee. James A. Haley VA Medical Center, Tampa, FL, 2000-2001.

Education Committee, Department of Psychiatry and Behavioral Neurosciences, University of South Florida Morsani College of Medicine. 1997-1999.

**Professional Society Membership**

Member, Researchers Against Alzheimer’s

Member, ISTAART (International Society to Advance Alzheimer's Research and Treatment); also member of ISTAART professional interest groups for Women Researchers and for Neuropsychiatric Symptoms

**Paid Professional Activity**

Advisory Board participant -Eisai (BAN2401 protocol development) February 2019

Advisory panel participant –Probiodrug (PQ912 protocol development through ADCS) July 2018

Advisory Board participant -Eisai (Aricept 23) 2010

Speakers Bureau –Forest (Namenda) 2010-2012

Advisory Board participant -Accera (Axona) 2009

Speaker’s Bureau –Novartis (Exelon patch) 2008-2013